Advertisement
Home »

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

Jan 15, 2024

ABOUT THE EXPERTS

  • Devalingam Mahalingam

    Northwestern University Medical School, Chicago, IL, USA. Mahalingam@nm.org.

    Wael Harb

    Horizon Oncology Center, Lafayette, IN, USA.

    Amita Patnaik

    South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.

    Andrea Bullock

    Beth Israel Deaconess Hospital, Boston, MA, USA.

    Randolph S Watnick

    Boston Children’s Hospital, Boston, MA, USA.

    Melanie Y Vincent

    Vigeo Therapeutics, Cambridge, MA, USA.

    Jian Jenny Chen

    Vigeo Therapeutics, Cambridge, MA, USA.

    Suming Wang

    Vigeo Therapeutics, Cambridge, MA, USA.

    Harold Pestana

    Vigeo Therapeutics, Cambridge, MA, USA.

    Judy Chao

    Vigeo Therapeutics, Cambridge, MA, USA.

    James Mahoney

    Vigeo Therapeutics, Cambridge, MA, USA.

    Michael Cieslewicz

    Vigeo Therapeutics, Cambridge, MA, USA.

    Jing Watnick

    Vigeo Therapeutics, Cambridge, MA, USA. Jing.Watnick@vigeotx.com.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement